{"id":"jnj-77242113","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Akathisia"}]},"_chembl":{"chemblId":"CHEMBL4802039","moleculeType":"Unknown","molecularWeight":"358.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE10A is predominantly expressed in medium spiny neurons of the striatum. By inhibiting PDE10A, the drug increases cyclic nucleotide levels (cAMP and cGMP), enhancing downstream signaling pathways involved in motor control and cognitive function. This mechanism is being explored for neuropsychiatric and movement disorders where striatal dysfunction plays a role.","oneSentence":"JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:36.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (exploratory)"}]},"trialDetails":[{"nctId":"NCT06095115","phase":"PHASE3","title":"A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-12","conditions":"Plaque Psoriasis","enrollment":684},{"nctId":"NCT06878404","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-21","conditions":"Arthritis, Psoriatic","enrollment":552},{"nctId":"NCT06807424","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-01-09","conditions":"Arthritis, Psoriatic","enrollment":750},{"nctId":"NCT06095102","phase":"PHASE3","title":"A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-12","conditions":"Plaque Psoriasis","enrollment":311},{"nctId":"NCT06934226","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-04-15","conditions":"Plaque Psoriasis","enrollment":752},{"nctId":"NCT07196722","phase":"PHASE2, PHASE3","title":"A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Crohn Disease","enrollment":1092},{"nctId":"NCT06295692","phase":"PHASE3","title":"A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2024-02-09","conditions":"Generalized Pustular Psoriasis, Erythrodermic Psoriasis","enrollment":19},{"nctId":"NCT06143878","phase":"PHASE3","title":"A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-01","conditions":"Plaque Psoriasis","enrollment":774},{"nctId":"NCT06220604","phase":"PHASE3","title":"A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-03-09","conditions":"Plaque Psoriasis","enrollment":731},{"nctId":"NCT07196748","phase":"PHASE3","title":"A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-01","conditions":"Colitis, Ulcerative","enrollment":882},{"nctId":"NCT06049017","phase":"PHASE2","title":"A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-09","conditions":"Colitis, Ulcerative","enrollment":252},{"nctId":"NCT05223868","phase":"PHASE2","title":"A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-02-03","conditions":"Plaque Psoriasis","enrollment":255},{"nctId":"NCT05364554","phase":"PHASE2","title":"A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-10","conditions":"Plaque Psoriasis","enrollment":227},{"nctId":"NCT05357755","phase":"PHASE2","title":"A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-13","conditions":"Plaque Psoriasis","enrollment":90},{"nctId":"NCT05062200","phase":"PHASE1","title":"A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-10-25","conditions":"Healthy","enrollment":36},{"nctId":"NCT05703841","phase":"PHASE1","title":"A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-14","conditions":"Healthy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PN-21235","PN-235","PN-21235,"],"phase":"phase_3","status":"active","brandName":"JNJ-77242113","genericName":"JNJ-77242113","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity. Used for Schizophrenia, Bipolar disorder (exploratory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}